Sign in

You're signed outSign in or to get full access.

Robbert Vorhoff

Director at Alignment Healthcare
Board

About Robbert Vorhoff

Robbert Vorhoff, age 46, is an independent director of Alignment Healthcare (ALHC) and has served on the Board since 2014. He is Managing Director, Investment Committee member, and Global Head of Healthcare at General Atlantic; he holds a B.S. in Commerce (Finance) from the University of Virginia. His core credentials cited by ALHC include health care industry expertise and capital markets experience .

Past Roles

OrganizationRoleTenureCommittees/Impact
General AtlanticManaging Director; Global Head of Healthcare; Investment Committee memberSince 2003 (joined GA in 2003) Growth investor/board governance across healthcare portfolio
Greenhill & Co.M&A and restructuring advisory; later Greenhill Capital Partners (private equity)Prior to 2003 Transaction execution and PE investing

External Roles

OrganizationRoleTypeTenure/Notes
Equality HealthBoard memberPrivateCurrent
Included HealthBoard memberPrivateCurrent
Marathon HealthBoard memberPrivateCurrent
NationsBenefitsBoard memberPrivateCurrent
Suvida HealthcareBoard memberPrivateCurrent
Eventus Whole HealthBoard memberPrivateCurrent
Author HealthBoard memberPrivateCurrent
Align Networks; Alternate Solutions Health Network; A Place for Mom; eviCore Healthcare; Landmark Health; Oak Street Health; WelbeHealth; OneOncology; MedExpressPrior board memberMix of private/public (Oak Street Health formerly public)Prior
Other public company boards (current)None disclosed

Board Governance

  • Committee assignments: Compensation Committee member (not Chair) .
  • Independence: Board determined Vorhoff is independent under Nasdaq/SEC rules (independence evaluated including affiliations with General Atlantic, ALHC’s Lead Sponsor) .
  • Attendance: In 2024, all directors except Dr. McClellan attended at least 75% of combined Board and committee meetings; the Board held 7 meetings; Compensation Committee held 9 .
  • Executive sessions: Independent directors meet in executive session at least quarterly; Board maintains a Lead Independent Director structure when Chair is not independent .

Fixed Compensation

Component (2024)AmountDetail
Fees Earned or Paid in Cash$16,875 Includes cash retainer elected and committee member fees (Compensation Committee members receive $7,500 annually in 2024)
Stock Awards (RSUs grant-date fair value)$250,000 Annual director equity; vesting on first anniversary of grant date
Total$266,875 Paid under Non-Employee Director Compensation Policy

Policy reference points:

  • 2024 aggregate annual director compensation value: $250,000 (cash retainer elected from $0–$100,000; balance in RSUs/restricted shares) .
  • Committee fees (2024): Compensation Committee Chair $20,000; members $7,500; Audit Chair $25,000; Audit members $10,000; NCGCC Chair $20,000; NCGCC members $7,500 .
  • 2025 aggregate increased to $290,000; certain committee retainers increased (e.g., Compensation Chair to $25,000; members to $10,000) .

Performance Compensation

ElementStructureMetricsVesting
Director equity grantsTime-based RSUsNone (no performance-based director metrics disclosed) RSUs vest on first anniversary of grant date; optional deferral elections available

ALHC’s performance share unit framework applies to executives, not directors; director awards are retainer-linked time-vested RSUs .

Other Directorships & Interlocks

ItemDisclosure
Compensation Committee interlocksNone among members (Kosecoff, McCarthy, Vorhoff) in 2024; no insider participation
Independent compensation consultantFW Cook engaged May 2024 for executive/director pay advice
Lead Sponsor influenceStockholders Agreement grants General Atlantic (Lead Sponsor) board designation rights based on ownership thresholds

Expertise & Qualifications

  • Health care industry expertise; capital markets experience (as cited by ALHC) .
  • Managing Director and Global Head of Healthcare at General Atlantic; extensive healthcare board experience across payors/providers/services .
  • Education: B.S. in Commerce (Finance) from University of Virginia .

Equity Ownership

MeasureValueNotes
Beneficial ownership (common shares)135,716 shares; <1% of outstanding
Unvested RSUs (as of 12/31/2024)50,000 RSUs
Stock optionsNone disclosed for Vorhoff
Pledging/Hedging policyCompany prohibits pledging and short sales; allows only long-term hedges with pre-clearance; anti-hedging/anti-pledging policies in place
Director stock ownership guidelinesCompany maintains officer/director ownership requirements; specific multiples not disclosed

Governance Assessment

  • Strengths: Independent status; active role on Compensation Committee; robust board processes (annual self-evaluations; executive sessions; clawback; anti-hedging/anti-pledging), and high overall director engagement (Board/committee attendance practices) .
  • Alignment: Director compensation is predominantly equity, with modest cash; Vorhoff elected minimal cash relative to equity ($16,875 cash; $250,000 RSUs), supporting ownership alignment .
  • Potential conflicts (monitoring focus): Vorhoff’s senior role at General Atlantic, ALHC’s Lead Sponsor (31.0% ownership), combined with GA’s board designation rights, can create perceived sponsor influence; Board explicitly considered GA affiliations in independence determinations; related-party transactions are overseen by the Audit Committee pursuant to policy .
  • RED FLAGS: None disclosed specific to Vorhoff (no related-party transactions or interlocks requiring disclosure; attendance met ≥75% threshold). Ongoing monitoring warranted for sponsor influence due to GA’s rights and portfolio overlaps in healthcare ecosystems .